Sofinnova, Polaris lead CHF 54m series-A for Noema

Gilde Healthcare, Invus and BioMed Partners also took part in the investment. In addition, Roche, a Swiss multinational healthcare company, received a shareholding in Noema in exchange for rights to four clinical-stage product candidates.

Following the deal, Polaris's Darren Carroll and Gilde's Arthur Franken will join Sofinnova's Antoine Papiernik on the company's board of directors.

Noema plans to use the fresh capital to fund the development of its clinical-stage pipeline composed of four candidates to treat orphan neurological disorders.

Sofinnova is a European life-sciences-dedicated venture capital firm headquartered in Paris, with offices in London and Milan. The firm is currently investing its Sofinnova Capital IX fund, which closed on €333m in October 2019. 

Previous funding
Noema was established in 2019 with capital provided through a seed investment financed by Sofinnova.

Company
Noema specialises in developing drugs for the treatment of orphan neurological disorders.

Its product candidates are developed in neurological indications with severe unmet need, such as seizures in tuberculosis sclerosis complex, trigeminal neuralgia, Tourette syndrome and other rare neurological disorders.

People
Sofinnova Partners – Antoine Papiernik (chair, managing partner).
Polaris Partners – Darren Carroll (partner).
Noema Pharma – Luigi Costa (CEO).

Advisers
Company – LifeSci Advisors (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Switzerland
• Sofinnova Partners